Advice

in the absence of a submission from the holder of the marketing authorisation:

ixazomib (Ninlaro®) is not recommended for use within NHSScotland.

Indication under review: in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download full details215KB (PDF)

Download

Medicine details

Medicine name:
ixazomib (Ninlaro)
SMC ID:
SMC2099
Indication:
in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
09 July 2018